Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228251 | 0.85 | ALDH1A1 (0.39) | ALDH1A1LMNAL3MBTL1RAB9APOLB | |
| SCHEMBL17141437 | 0.81 | POLB (0.43) | ALDH1A1LMNAL3MBTL1RAB9APOLB | |
| SCHEMBL1750237 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNAL3MBTL1RAB9APOLB | |
| SCHEMBL6826837 | 0.79 | CASP1 (0.43) | ALDH1A1LMNAL3MBTL1RAB9APOLB | |
| SCHEMBL15633425 | 0.79 | KDM4E (0.46) | ALDH1A1LMNAL3MBTL1RAB9APOLB | |
| SCHEMBL17773615 | 0.73 | ALDH1A1 (0.34) | ALDH1A1LMNAL3MBTL1RAB9ATDP1 | |
| SCHEMBL1749975 | 0.72 | HMGCR (0.40) | HMGCRALDH1A1L3MBTL1HSP90AB1POLB | |
| SCHEMBL24493747 | 0.69 | HMGCR (0.42) | HMGCRL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL27978039 | 0.69 | HMGCR (0.42) | HMGCRALDH1A1L3MBTL1HSP90AB1POLB | |
| SCHEMBL15633238 | 0.68 | PDE4A (0.38) | ALDH1A1LMNAL3MBTL1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | HMGCR 672/4885ALDH1A1 2673/4885LMNA 807/4885 |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | HMGCR 4499/4885ALDH1A1 3043/4885LMNA 919/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | HMGCR 4499/4885ALDH1A1 3043/4885LMNA 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.